Nanopore Sequencing and Machine Learning Powered-Platform Enables High-Accuracy, High-Frequency COVID-19 Testing
By HospiMedica International staff writers Posted on 14 Oct 2020 |
Illustration
A newly-launched nanopore sequencing and machine learning powered platform enables high-accuracy, high-frequency, low-cost COVID-19 and respiratory pathogen testing, allowing businesses, educational institutions, and other points of frequent gathering to resume operations safely.
The new AMPD platform launched by Angstrom Bio, Inc. (Austin, TX, USA) leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza. At the heart of AMPD is a novel nucleotide chemistry and computational biology platform designed to harness the bandwidth and resolution of Oxford Nanopore Technologies’ (Oxford, UK) nanopore Third-Generation Sequencing (TGS) systems. Unlike diagnostic systems that rely upon fluorescence-driven workflows for diagnostic analysis, nanopore TGS counts individual DNA molecules that pass through each of hundreds of nano-scale pores in a specially-designed membrane. The combination of single-molecule resolution and parallelism allow for the processing of tens of thousands of diagnostic results per AMPD run, while enabling orders of magnitude greater sensitivity than is currently available. This makes AMPD ideal for parties that require timely access to affordable, repeated testing, but that cannot compromise safety.
AMPD utilizes a simple, self-collected saliva sample that not only avoids the discomfort associated with traditional swabs. Samples are registered and collected on-site using simple workflows then processed in an automated AMPD facility, with results delivered within 24 hours. Angstrom intends to bring more than one million results per day online in 2021, at prices that enable nearly any organization to have access to repeated, high-quality testing.
“By leveraging the extraordinary resolution and bandwidth of nanopore sequencing and the power of our machine learning-driven diagnostic pipelines, and by rethinking pre-COVID-19 diagnostic workflows, we have been able to design a platform that can provide the extreme scale and accuracy required to meet the unprecedented challenges posed by COVID-19,” said Carlos F. Santos, Ph.D., Angstrom's CEO.
Related Links:
Angstrom Bio, Inc.
Oxford Nanopore Technologies
The new AMPD platform launched by Angstrom Bio, Inc. (Austin, TX, USA) leverages the extreme resolution and bandwidth of nanopore sequencing to provide the accuracy and volume necessary to detect the earliest stages of exposure to pathogens like SARS-CoV-2 and influenza. At the heart of AMPD is a novel nucleotide chemistry and computational biology platform designed to harness the bandwidth and resolution of Oxford Nanopore Technologies’ (Oxford, UK) nanopore Third-Generation Sequencing (TGS) systems. Unlike diagnostic systems that rely upon fluorescence-driven workflows for diagnostic analysis, nanopore TGS counts individual DNA molecules that pass through each of hundreds of nano-scale pores in a specially-designed membrane. The combination of single-molecule resolution and parallelism allow for the processing of tens of thousands of diagnostic results per AMPD run, while enabling orders of magnitude greater sensitivity than is currently available. This makes AMPD ideal for parties that require timely access to affordable, repeated testing, but that cannot compromise safety.
AMPD utilizes a simple, self-collected saliva sample that not only avoids the discomfort associated with traditional swabs. Samples are registered and collected on-site using simple workflows then processed in an automated AMPD facility, with results delivered within 24 hours. Angstrom intends to bring more than one million results per day online in 2021, at prices that enable nearly any organization to have access to repeated, high-quality testing.
“By leveraging the extraordinary resolution and bandwidth of nanopore sequencing and the power of our machine learning-driven diagnostic pipelines, and by rethinking pre-COVID-19 diagnostic workflows, we have been able to design a platform that can provide the extreme scale and accuracy required to meet the unprecedented challenges posed by COVID-19,” said Carlos F. Santos, Ph.D., Angstrom's CEO.
Related Links:
Angstrom Bio, Inc.
Oxford Nanopore Technologies
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans